Inovio Pharmaceuticals Inc vs Knight-Swift Transportation Holdings Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Knight-Swift Transportation Holdings Inc. trades at $64.4 (market cap $10.59B). The key difference: Knight-Swift Transportation Holdings Inc. is far larger — about 94.4× Inovio Pharmaceuticals Inc's market cap, and Knight-Swift Transportation Holdings Inc. pays a 1.23% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Knight-Swift Transportation Holdings Inc. for 1 Days on average.
| INO | KNX | |
|---|---|---|
Market Cap | $112.19M | $10.59B |
Volume | 3,201,278 | 2,972,511 |
Sector | Health | Industrials |
52-Week High | $2.65 | $82.45 |
52-Week Low | $0.66 | $41.68 |
Typical Hold Time | 43 Days | 1 Days |
Enterprise Value | $83.51M | $13.09B |
Dividend Yield | — | 1.23% |
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Knight-Swift provides truckload, less-than-truckload, logistics, and freight management services. It operates a large transportation network across North America.
Read more on KNX →